PATENT CLAIM ANALYSIS

Application Number: 16163380
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Claim (Index 14):
The method of  claim 13 , wherein the VMAT2-mediated disorder is a chronic hyperkinetic movement disorder, Huntington's disease, hemiballismus, senile chorea, a tic disorder, tardive dyskinesia, dystonia, Tourette's syndrome, depression, cancer, rheumatoid arthritis, psychosis, multiple sclerosis, or asthma.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 97.0
- Lexical Diversity: 1.02857
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14479823', '15071797', '14245024', '15044655', '14030322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8137542055266374
- 35 USC 102 Novelty (BERT): 0.5757372548864003
- Combined Prediction Score: 0.7899525104626137
- Mean Citation Score: 488.218912
- Max Citation Score: 508.84766
- Similarity Product: 314.92160148172377

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test